Publication Information

{'id': 'https://openalex.org/W2062691140', 'doi': 'https://doi.org/10.1517/14740338.2015.1021774', 'title': 'Safety of pembrolizumab for the treatment of melanoma', 'display_name': 'Safety of pembrolizumab for the treatment of melanoma', 'publication_year': 2015, 'publication_date': '2015-04-30', 'ids': {'openalex': 'https://openalex.org/W2062691140', 'doi': 'https://doi.org/10.1517/14740338.2015.1021774', 'mag': '2062691140', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/25927979'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1517/14740338.2015.1021774', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S20709540', 'display_name': 'Expert Opinion on Drug Safety', 'issn_l': '1474-0338', 'issn': ['1474-0338', '1744-764X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320547', 'host_organization_name': 'Taylor & Francis', 'host_organization_lineage': ['https://openalex.org/P4310320547'], 'host_organization_lineage_names': ['Taylor & Francis'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'review', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5058642751', 'display_name': 'Juan Martin‐Liberal', 'orcid': 'https://orcid.org/0000-0003-2552-5172'}, 'institutions': [{'id': 'https://openalex.org/I4210121186', 'display_name': 'Royal Marsden Hospital', 'ror': 'https://ror.org/034vb5t35', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038', 'https://openalex.org/I4210121186']}, {'id': 'https://openalex.org/I285663978', 'display_name': 'Weatherford College', 'ror': 'https://ror.org/02xwsbr93', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I285663978']}, {'id': 'https://openalex.org/I1325846038', 'display_name': 'Royal Marsden NHS Foundation Trust', 'ror': 'https://ror.org/0008wzh48', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038']}], 'countries': ['GB', 'US'], 'is_corresponding': False, 'raw_author_name': 'Juan Martin-Liberal', 'raw_affiliation_strings': ['+44 20 7811 8103', 'The Royal Marsden Hospital, Fulham Road SW3 6JJ, London, UK +44 20 7811 8576'], 'affiliations': [{'raw_affiliation_string': 'The Royal Marsden Hospital, Fulham Road SW3 6JJ, London, UK +44 20 7811 8576', 'institution_ids': ['https://openalex.org/I4210121186', 'https://openalex.org/I1325846038']}, {'raw_affiliation_string': '+44 20 7811 8103', 'institution_ids': ['https://openalex.org/I285663978']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5033217800', 'display_name': 'Tiana Kordbacheh', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1325846038', 'display_name': 'Royal Marsden NHS Foundation Trust', 'ror': 'https://ror.org/0008wzh48', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038']}, {'id': 'https://openalex.org/I4210121186', 'display_name': 'Royal Marsden Hospital', 'ror': 'https://ror.org/034vb5t35', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038', 'https://openalex.org/I4210121186']}, {'id': 'https://openalex.org/I285663978', 'display_name': 'Weatherford College', 'ror': 'https://ror.org/02xwsbr93', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I285663978']}], 'countries': ['GB', 'US'], 'is_corresponding': False, 'raw_author_name': 'Tiana Kordbacheh', 'raw_affiliation_strings': ['+44 20 7811 8103', 'The Royal Marsden Hospital, Fulham Road SW3 6JJ, London, UK +44 20 7811 8576'], 'affiliations': [{'raw_affiliation_string': 'The Royal Marsden Hospital, Fulham Road SW3 6JJ, London, UK +44 20 7811 8576', 'institution_ids': ['https://openalex.org/I1325846038', 'https://openalex.org/I4210121186']}, {'raw_affiliation_string': '+44 20 7811 8103', 'institution_ids': ['https://openalex.org/I285663978']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5076054848', 'display_name': 'James Larkin', 'orcid': 'https://orcid.org/0000-0001-5569-9523'}, 'institutions': [{'id': 'https://openalex.org/I1325846038', 'display_name': 'Royal Marsden NHS Foundation Trust', 'ror': 'https://ror.org/0008wzh48', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038']}, {'id': 'https://openalex.org/I4210121186', 'display_name': 'Royal Marsden Hospital', 'ror': 'https://ror.org/034vb5t35', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038', 'https://openalex.org/I4210121186']}, {'id': 'https://openalex.org/I285663978', 'display_name': 'Weatherford College', 'ror': 'https://ror.org/02xwsbr93', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I285663978']}], 'countries': ['GB', 'US'], 'is_corresponding': False, 'raw_author_name': 'James Larkin', 'raw_affiliation_strings': ['+44 20 7811 8103', 'The Royal Marsden Hospital, Fulham Road SW3 6JJ, London, UK +44 20 7811 8576'], 'affiliations': [{'raw_affiliation_string': 'The Royal Marsden Hospital, Fulham Road SW3 6JJ, London, UK +44 20 7811 8576', 'institution_ids': ['https://openalex.org/I1325846038', 'https://openalex.org/I4210121186']}, {'raw_affiliation_string': '+44 20 7811 8103', 'institution_ids': ['https://openalex.org/I285663978']}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 3, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.755, 'has_fulltext': False, 'cited_by_count': 33, 'citation_normalized_percentile': {'value': 0.630154, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 94, 'max': 95}, 'biblio': {'volume': '14', 'issue': '6', 'first_page': '957', 'last_page': '964'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11491', 'display_name': 'CAR-T cell therapy research', 'score': 0.9989, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11533', 'display_name': 'Melanoma and MAPK Pathways', 'score': 0.9966, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.9935148}, {'id': 'https://openalex.org/C2781433595', 'wikidata': 'https://www.wikidata.org/wiki/Q2459042', 'display_name': 'Ipilimumab', 'level': 4, 'score': 0.92483914}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9110309}, {'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.8575934}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.68303907}, {'id': 'https://openalex.org/C2777658100', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Melanoma', 'level': 2, 'score': 0.5666547}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.489631}, {'id': 'https://openalex.org/C3454156', 'wikidata': 'https://www.wikidata.org/wiki/Q1144241', 'display_name': 'Side effect (computer science)', 'level': 2, 'score': 0.47982478}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.4455392}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.40393466}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.3425913}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.1450251}, {'id': 'https://openalex.org/C41008148', 'wikidata': 'https://www.wikidata.org/wiki/Q21198', 'display_name': 'Computer science', 'level': 0, 'score': 0.0}, {'id': 'https://openalex.org/C199360897', 'wikidata': 'https://www.wikidata.org/wiki/Q9143', 'display_name': 'Programming language', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': True}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': True}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000818', 'descriptor_name': 'Animals', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000911', 'descriptor_name': 'Antibodies, Monoclonal', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D000911', 'descriptor_name': 'Antibodies, Monoclonal', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000074324', 'descriptor_name': 'Ipilimumab', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077594', 'descriptor_name': 'Nivolumab', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D061026', 'descriptor_name': 'Programmed Cell Death 1 Receptor', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D061026', 'descriptor_name': 'Programmed Cell Death 1 Receptor', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': False}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1517/14740338.2015.1021774', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S20709540', 'display_name': 'Expert Opinion on Drug Safety', 'issn_l': '1474-0338', 'issn': ['1474-0338', '1744-764X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320547', 'host_organization_name': 'Taylor & Francis', 'host_organization_lineage': ['https://openalex.org/P4310320547'], 'host_organization_lineage_names': ['Taylor & Francis'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/25927979', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.86, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 39, 'referenced_works': ['https://openalex.org/W1581027083', 'https://openalex.org/W1971208896', 'https://openalex.org/W1983509391', 'https://openalex.org/W1984545852', 'https://openalex.org/W1990675339', 'https://openalex.org/W1990779902', 'https://openalex.org/W2016055985', 'https://openalex.org/W2016983859', 'https://openalex.org/W2019607817', 'https://openalex.org/W2029086221', 'https://openalex.org/W2040956995', 'https://openalex.org/W2057499380', 'https://openalex.org/W2057574963', 'https://openalex.org/W2080878900', 'https://openalex.org/W2085357061', 'https://openalex.org/W2097995306', 'https://openalex.org/W2098906780', 'https://openalex.org/W2100696012', 'https://openalex.org/W2101653483', 'https://openalex.org/W2107402388', 'https://openalex.org/W2107484016', 'https://openalex.org/W2107752337', 'https://openalex.org/W2109653150', 'https://openalex.org/W2112387900', 'https://openalex.org/W2117692326', 'https://openalex.org/W2118471749', 'https://openalex.org/W2118982164', 'https://openalex.org/W2123363005', 'https://openalex.org/W2124089048', 'https://openalex.org/W2128035403', 'https://openalex.org/W2131577873', 'https://openalex.org/W2136746908', 'https://openalex.org/W2143163879', 'https://openalex.org/W2155464214', 'https://openalex.org/W2158393416', 'https://openalex.org/W2158840473', 'https://openalex.org/W2169794517', 'https://openalex.org/W2249078564', 'https://openalex.org/W93540796'], 'related_works': ['https://openalex.org/W3215044659', 'https://openalex.org/W3185931698', 'https://openalex.org/W3029766637', 'https://openalex.org/W3021504039', 'https://openalex.org/W3016822790', 'https://openalex.org/W2773756552', 'https://openalex.org/W2580215808', 'https://openalex.org/W2466451466', 'https://openalex.org/W2285109017', 'https://openalex.org/W2155654588'], 'abstract_inverted_index': {'Introduction:': [0], 'The': [1], 'immune': [2, 131, 172], 'checkpoint': [3, 132, 173], 'inhibitor': [4], 'pembrolizumab': [5, 99, 177], 'is': [6, 42, 127, 141], 'the': [7, 14, 21, 70, 82, 94, 113, 116], 'first': [8], 'anti-programmed-death-1': [9], '(PD-1)': [10], 'drug': [11, 145], 'licensed': [12], 'by': [13, 171], 'FDA.': [15], 'It': [16], 'has': [17], 'been': [18], 'approved': [19], 'for': [20, 81], 'treatment': [22], 'of': [23, 33, 75, 85, 98, 110, 115, 124, 167, 181], 'advanced': [24], 'melanoma,': [25], 'thanks': [26], 'to': [27], 'its': [28, 36, 108, 122], 'positive': [29], 'results': [30], 'in': [31, 100, 119, 159, 184], 'terms': [32], 'efficacy': [34, 97], 'and': [35, 54, 73, 96, 112, 137, 156, 164], 'favorable': [37], 'toxicity': [38], 'profile.': [39], 'However,': [40, 151], 'it': [41], 'not': [43, 149], 'exempt': [44], 'from': [45], 'side': [46, 77, 125, 168], 'effects.': [47], 'In': [48, 91], 'general,': [49], 'these': [50, 152], 'are': [51, 59, 79, 102, 148, 153], 'usually': [52, 154], 'mild': [53, 155], 'easily': [55, 157], 'manageable': [56, 158], 'but': [57, 146], 'there': [58], 'pembrolizumab-induced': [60], 'immune-related': [61], 'adverse': [62], 'events': [63], '(irAEs)': [64], 'that': [65], 'can': [66], 'be': [67, 179], 'severe.': [68], 'Therefore,': [69], 'understanding,': [71], 'diagnosis': [72, 163], 'management': [74, 166], 'those': [76], 'effects': [78, 126, 169], 'essential': [80], 'optimal': [83], 'care': [84], 'patients': [86], 'treated': [87], 'with': [88, 129], 'pembrolizumab.Areas': [89], 'covered:': [90], 'this': [92], 'article,': [93], 'safety': [95], 'melanoma': [101], 'extensively': [103], 'reviewed': [104], 'as': [105, 107, 135, 176], 'well': [106], 'mechanism': [109], 'action': [111], 'role': [114], 'PD-1': [117], 'pathway': [118], 'cancer.': [120], 'Also,': [121], 'profile': [123], 'compared': [128], 'other': [130], 'inhibitors': [133, 174], 'such': [134, 175], 'ipilimumab': [136], 'nivolumab.Expert': [138], 'opinion:': [139], 'Pembrolizumab': [140], 'generally': [142], 'a': [143], 'well-tolerated': [144], 'irAEs': [147], 'infrequent.': [150], 'most': [160], 'cases.': [161], 'Early': [162], 'correct': [165], 'induced': [170], 'should': [178], 'areas': [180], 'further': [182], 'work': [183], 'forthcoming': [185], 'years.': [186]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2062691140', 'counts_by_year': [{'year': 2024, 'cited_by_count': 4}, {'year': 2023, 'cited_by_count': 2}, {'year': 2022, 'cited_by_count': 4}, {'year': 2021, 'cited_by_count': 1}, {'year': 2019, 'cited_by_count': 5}, {'year': 2018, 'cited_by_count': 4}, {'year': 2017, 'cited_by_count': 4}, {'year': 2016, 'cited_by_count': 7}, {'year': 2015, 'cited_by_count': 2}], 'updated_date': '2024-12-17T15:25:18.298286', 'created_date': '2016-06-24'}